PFE Stock DD Pfizer, Inc. 09/26/2014 00:09:00

New Post Public Reply Private Reply Replies (0) Message Board

Sep 26, 2014 at 1:09 AM

PFE Pfizer, Inc. $PFE Company Overview

Stock Message Board Recent Posts http://investorshangout.com/search?q=PFE&...mp;yt0=Go!

Last Updated: 09/26/2014 00:08:55

Current Price and Quotes
Last Price 29.98
Previous Close 30.31 Open 30.33
Daily Range 29.97 - 30.37 52wk Range 27.87 - 32.96
Volume 22,601,560 Dividend 1.04
Average Vol (30d) 21,117,817 Yield 3.469

Financials
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 51,584,000 54,657,000 61,035,000 65,165,000
Cost of Revenue 9,586,000 9,821,000 12,500,000 14,788,000
Gross Profit 41,998,000 44,836,000 48,535,000 50,377,000
Operating Expenses

Research and Development 6,678,000 7,482,000 8,681,000 9,483,000
Sales, General and Admin. 14,355,000 15,171,000 17,581,000 18,973,000
Non-Recurring Items 1,182,000 1,810,000 2,841,000 3,145,000
Other 4,599,000 5,109,000 5,465,000 5,364,000
Operating Income 15,184,000 15,264,000 13,967,000 13,412,000
Income From Continuing Operations

Add'l Income/Expense Items 532,000 (4,022,000) (2,486,000) (3,941,000)
Earnings Before Interest and Tax 15,716,000 11,242,000 11,481,000 9,471,000
Interest Expense - - - -
Earnings Before Tax 15,716,000 11,242,000 11,481,000 9,471,000
Income Tax 4,306,000 2,221,000 3,621,000 1,153,000
Minority Interest 69,000 28,000 40,000 31,000
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations 11,410,000 9,021,000 7,860,000 8,318,000
Non Recurring Events

Discontinued Operations 10,662,000 5,577,000 2,189,000 (30,000)
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income 22,003,000 14,570,000 10,009,000 8,257,000
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders 22,003,000 14,570,000 10,009,000 8,257,000

Recent News

Sep 25, 2014 Pfizer Completes Acquisition Of InnoPharma
Sep 24, 2014 Active Equities to Watch in Pharma Industry - Pfizer, BioDelivery Sciences Intl., Repros Therapeutics, Catalent, and Nektar Therapeutics
Sep 23, 2014 Pfizer Invites Public to View and Listen to Webcast of October 28 Conference Call with Analysts
Sep 23, 2014 Kim Cattrall Encourages Women to Embrace Menopause with Style
Sep 22, 2014 Licensing Agreements, Results of Clinical Trials, and Acquisitions - Research Reports on Gilead, AbbVie, Pfizer, Auxilium and Endo
Sep 22, 2014 Circle Pharma Announces Receipt of Seed Funding and Initiation of Two Collaborations
Sep 22, 2014 Bristol-Myers Squibb and Pfizer Announce Charitable Donations of More Than $1 Million to Support Cardiovascular Education for Patients and Caregivers
Sep 19, 2014 Pfizer Foundation Provides $2 Million In Grants To Support 'Last-Mile' Vaccine Coverage In Africa
Sep 16, 2014 MedGenesis Enters Into Agreement with Pfizer Inc. for Potential Treatments for Parkinson's Disease
Sep 12, 2014 Study Results, New Collaboration, Drug Designation, Technical Update, and Completion of Transaction - Research Reports on Gilead, AbbVie, Pfizer, United Therapeutics and Brookdale

1
2
3
4
5
6
7
next >